Currently, there is hardly any tangible data available in the literature pertaining to the possible role of the MRAS gene polymorphism in cardiovascular risk traits for CAD, such as obesity, hypertension (HTN), type 2 diabetes mellitus (T2DM) or dyslipidaemic disorders. This evidence concerns the gene MRAS and hypertensive disorder.